Abstract:Radiotherapy (RT) and immunotherapy (IT) are the powerful tools for cancer treatment which act through the stimulation of immune response, and evidence suggest that combinatorial actions of these therapies may augment each other's beneficial effect through complex synergistic mechanisms. These molecular strategies are designed to target rapidly dividing cancer cells by either directly or indirectly inducing DNA damage. However, when cells detect DNA damage, they activate a range of signalling pathways known as the DNA damage response (DDR) to repair. Strategies are being developed to interfere with the DDR pathways in cancer cells to ensure their damage-induced degeneration. The stability of a cell's genetic material is largely dependent on the efficacy of DNA repair and therefore, an in-depth understanding of DNA damages and repair mechanism(s) in cancer cells is important to develop a promising therapeutic strategies for ensuring the efficacy of damage-induced tumor cell death. In recent years, a wide range of small molecule drugs have been developed which are currently being employed to combat the DNA repair deficiencies associated with tumor cells. Sequential or concurrent use of these two modalities significantly enhances the anti-tumor response, however with a concurrent probability of increased incidence of symptomatic adverse effects. With advent of newer IT agents, and administration of higher doses of radiation per fraction, such effects are more difficult to predict owing to the paucity of randomized trial data. It is well established that anti cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4), anti- Programmed cell death protein 1(PD-1), anti-Programmed cell death one ligand 1 (PD-L1) can be safely administered with RT and many studies have demonstrated survival benefit with such combination for patients with metastatic malignancy. However, the biology of radioimmunotherapy (RT/IT) is still an open area where research need to be focused to determine optimum dosage specially the interaction of the RT/IT pathways to determine optimum dosing schedule. In the current article we have summarised the possible intracellular immunological events that might be triggered when RT and IT modalities are combined with the DDR antagonists and highlighted present clinical practices, outcome, and toxicity profile of this novel treatment strategy.

Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy

Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review

The future of cancer treatment: combining radiotherapy with immunotherapy

Immune targets in the tumor microenvironment treated by radiotherapy

Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments

Radiotherapy-activated tumor immune microenvironment: Realizing radiotherapy-immunity combination therapy strategies

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates

Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects

Beyond Success: Unveiling the Hidden Potential of Radiotherapy and Immunotherapy in Solid Tumors

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Radiation-induced Tumor Immune Microenvironments and Potential Targets for Combination Therapy

Radiation‐Induced Immunogenic Cell Death for Cancer Radioimmunotherapy

Treatment Strategies and Molecular Mechanism of Radiotherapy Combined with Immunotherapy in Colorectal Cancer

Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review

Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality

Challenges in the combination of radiotherapy and immunotherapy for breast cancer

Exploring low-dose radiotherapy to overcome radio-immunotherapy resistance

Irradiated Engineered Tumor Cell-Derived Microparticles Remodel the Tumor Immune Microenvironment and Enhance Antitumor Immunity.